Drug Search Results
More Filters [+]

Lasmiditan

Alternative Names: lasmiditan, col-144, reyvow
Latest Update: 2024-08-06
Latest Update Note: News Article

Product Description

Lasmiditan is used to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Lasmiditan is in a class of medications called selective serotonin receptor agonists. Lasmiditan may work by stopping pain signals from being sent to the brain and stopping inflammation of the nerves that cause symptoms of migraine. Lasmiditan does not prevent migraine attacks or reduce the number of headaches you have. (Sourced from: https://medlineplus.gov/druginfo/meds/a620015.html)

Mechanisms of Action: 5-HT1F Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Mexico | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Turkey | United Arab Emirates | United States

Approved Indications: Migraine Disorders | Migraine with Aura | Migraine without Aura

Known Adverse Events: Dizziness | Paresthesia

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lasmiditan

Countries in Clinic: Belgium, China, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Singapore, Spain, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Migraine Disorders

Phase 1: Healthy Volunteers|Migraine with Aura|Migraine without Aura

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

H8H-MC-LAHW

P3

Recruiting

Migraine Disorders

2031-01-31

H8H-MC-LAHV

P3

Recruiting

Migraine Disorders

2029-11-30

PIONEER-PEDS2

P3

Recruiting

Migraine Disorders

2026-03-31

PIONEER-PEDS1

P3

Recruiting

Migraine Disorders

2025-01-31

Recent News Events